Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3
Completed · Phase 2 · Has a placebo group
Conditions studied: Atopic Dermatitis, Psoriasis
In brief
This study will examine whether administration of oral Vitamin D3 given over 21 days will change the antimicrobial peptide expression in the skin or saliva of subjects with Atopic Dermatitis (AD). This study will help researchers determine if the lack of the expression of antimicrobial peptides in individuals with AD plays a role in the susceptibility to eczema vaccinatum (EV).
Key facts
- Study ID
- NCT00789880
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 82
- Starts
- 2008-12-01
- Expected to finish
- 2009-12-01
- Last updated by the study team
- 2017-04-12
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
Where it is running
- University of California, San Diego — San Diego, California, United States
- National Jewish Health — Denver, Colorado, United States
- Oregon Health & Science University — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.